Short Interest in Bone Biologics Corp. (NASDAQ:BBLG) Decreases By 60.5%

Bone Biologics Corp. (NASDAQ:BBLG) was the target of a significant decline in short interest in the month of July. As of July 15th, there was short interest totaling 26,560 shares, a decline of 60.5% from the June 30th total of 67,279 shares. Based on an average daily volume of 70,934 shares, the short-interest ratio is currently 0.4 days. Approximately 1.6% of the shares of the company are sold short.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Bone Biologics stock. DRW Securities LLC increased its position in Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,576 shares of the company’s stock after buying an additional 12,549 shares during the period. DRW Securities LLC owned 1.31% of Bone Biologics worth $34,000 at the end of the most recent quarter. 34.30% of the stock is currently owned by hedge funds and other institutional investors.

Bone Biologics Stock Down 6.5%

NASDAQ BBLG traded down $0.07 during trading hours on Tuesday, reaching $0.96. The company’s stock had a trading volume of 15,862 shares, compared to its average volume of 38,892. Bone Biologics has a 1 year low of $0.98 and a 1 year high of $4.13. The company has a market capitalization of $1.73 million, a price-to-earnings ratio of -0.44 and a beta of 0.90. The firm’s 50-day moving average price is $1.29 and its 200-day moving average price is $1.33.

Bone Biologics (NASDAQ:BBLG) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.43). Equities research analysts anticipate that Bone Biologics will post -1.17 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bone Biologics in a research report on Friday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Bone Biologics Company Profile

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.